Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 290

1.

Association Between Liver Fibrosis and Serum Prostate Specific Antigen (PSA) Among US Men: National Health and Nutrition Examination Survey (NHANES) 2001-2010.

Wang A, Lazo M, Carter HB, Groopman JD, Nelson WG, Platz EA.

Cancer Epidemiol Biomarkers Prev. 2019 Jun 3. pii: cebp.0145.2019. doi: 10.1158/1055-9965.EPI-19-0145. [Epub ahead of print]

PMID:
31160348
2.

Editorial Comment.

Carter HB.

J Urol. 2019 May;201(5):922. doi: 10.1097/01.JU.0000554387.61658.af. No abstract available.

PMID:
30821621
3.

ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS.

Lange JM, Gulati R, Leonardson AS, Lin DW, Newcomb LF, Trock BJ, Carter HB, Cooperberg MR, Cowan JE, Klotz LH, Etzioni R.

Ann Appl Stat. 2018 Sep;12(3):1773-1795. doi: 10.1214/17-AOAS1130. Epub 2018 Sep 11.

4.

Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.

Carter HB, Helfand B, Mamawala M, Wu Y, Landis P, Yu H, Wiley K, Na R, Shi Z, Petkewicz J, Shah S, Fantus RJ, Novakovic K, Brendler CB, Zheng SL, Isaacs WB, Xu J.

Eur Urol. 2019 May;75(5):743-749. doi: 10.1016/j.eururo.2018.09.021. Epub 2018 Oct 8.

PMID:
30309687
5.

PTEN status assessment in the Johns Hopkins active surveillance cohort.

Tosoian JJ, Guedes LB, Morais CL, Mamawala M, Ross AE, De Marzo AM, Trock BJ, Han M, Carter HB, Lotan TL.

Prostate Cancer Prostatic Dis. 2019 Mar;22(1):176-181. doi: 10.1038/s41391-018-0093-2. Epub 2018 Oct 2.

6.

Clinical Evaluation of an Individualized Risk Prediction Tool for Men on Active Surveillance for Prostate Cancer.

Huntley JH, Coley RY, Carter HB, Radhakrishnan A, Krakow M, Pollack CE.

Urology. 2018 Nov;121:118-124. doi: 10.1016/j.urology.2018.08.021. Epub 2018 Aug 30.

PMID:
30171924
7.

Older Age Predicts Biopsy and Radical Prostatectomy Grade Reclassification to Aggressive Prostate Cancer in Men on Active Surveillance.

Druskin SC, Mamawala M, Tosoian JJ, Epstein JI, Pavlovich CP, Carter HB, Trock BJ.

J Urol. 2019 Jan;201(1):98-104. doi: 10.1016/j.juro.2018.08.023.

PMID:
30114397
8.

Germline mutations in PPFIBP2 are associated with lethal prostate cancer.

Wu Y, Yu H, Zheng SL, Feng B, Kapron AL, Na R, Boyle JL, Shah S, Shi Z, Ewing CM, Wiley KE, Luo J, Walsh PC, Carter HB, Helfand BT, Cooney KA, Xu J, Isaacs WB.

Prostate. 2018 Dec;78(16):1222-1228. doi: 10.1002/pros.23697. Epub 2018 Jul 24.

PMID:
30043417
9.

Stratifying Risk for Men With Low-Volume Intermediate-Risk Prostate Cancer-Reply.

Patel HD, Tosoian JJ, Carter HB, Epstein JI.

JAMA Oncol. 2018 Aug 1;4(8):1133-1134. doi: 10.1001/jamaoncol.2018.0754. No abstract available.

PMID:
29852039
10.

Prostate-Specific Antigen (PSA) Screening for Prostate Cancer: Revisiting the Evidence.

Carter HB.

JAMA. 2018 May 8;319(18):1866-1868. doi: 10.1001/jama.2018.4914. No abstract available.

PMID:
29800999
11.

Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.

Patel HD, Gupta M, Tosoian JJ, Carter HB, Partin AW, Epstein JI.

J Urol. 2018 Nov;200(5):1068-1074. doi: 10.1016/j.juro.2018.04.058. Epub 2018 Apr 17.

PMID:
29673946
12.

A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer.

Wu Y, Yu H, Zheng SL, Na R, Mamawala M, Landis T, Wiley K, Petkewicz J, Shah S, Shi Z, Novakovic K, McGuire M, Brendler CB, Ding Q, Helfand BT, Carter HB, Cooney KA, Isaacs WB, Xu J.

Prostate. 2018 Jun;78(8):607-615. doi: 10.1002/pros.23505. Epub 2018 Mar 9.

PMID:
29520813
13.

Risk Stratification in Active Surveillance: A Dynamic, Ever-Evolving Practice.

Tosoian JJ, Carter HB.

Eur Urol. 2018 May;73(5):713-714. doi: 10.1016/j.eururo.2018.02.006. Epub 2018 Feb 17. No abstract available.

PMID:
29458984
14.

Targeted antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy during active surveillance: Effect on hospitalization.

Cheung C, Patel HD, Landis P, Carter HB, Han M.

Urol Oncol. 2018 Apr;36(4):158.e7-158.e12. doi: 10.1016/j.urolonc.2017.12.005. Epub 2017 Dec 26.

PMID:
29288004
15.

Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.

Druskin SC, Tosoian JJ, Young A, Collica S, Srivastava A, Ghabili K, Macura KJ, Carter HB, Partin AW, Sokoll LJ, Ross AE, Pavlovich CP.

BJU Int. 2018 Apr;121(4):619-626. doi: 10.1111/bju.14098. Epub 2018 Jan 9.

16.

Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.

Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R.

Ann Intern Med. 2018 Jan 2;168(1):1-9. doi: 10.7326/M17-0548. Epub 2017 Nov 28.

17.

Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.

Tosoian JJ, Mamawala M, Patel HD, Alam R, Epstein JI, Ross AE, Carter HB.

J Urol. 2018 Apr;199(4):954-960. doi: 10.1016/j.juro.2017.10.029. Epub 2017 Oct 24. Erratum in: J Urol. 2018 May 8;:.

PMID:
29074222
18.
19.

Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Con.

Tosoian JJ, Carter HB.

J Urol. 2017 Nov;198(5):997-999. doi: 10.1016/j.juro.2017.08.088. Epub 2017 Sep 22. Review. No abstract available.

PMID:
28947084
20.

Informational needs during active surveillance for prostate cancer: A qualitative study.

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Ciprut S, Sedlander E.

Patient Educ Couns. 2018 Feb;101(2):241-247. doi: 10.1016/j.pec.2017.08.022. Epub 2017 Sep 1.

21.

Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy.

Tosoian JJ, Alam R, Ball MW, Carter HB, Epstein JI.

Nat Rev Urol. 2018 Jan;15(1):55-66. doi: 10.1038/nrurol.2017.134. Epub 2017 Aug 31. Review.

PMID:
28858331
22.

Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.

Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.

Eur Urol. 2017 Dec;72(6):899-907. doi: 10.1016/j.eururo.2017.07.018. Epub 2017 Aug 23.

23.

Adverse Pathologic Findings for Men Electing Immediate Radical Prostatectomy: Defining a Favorable Intermediate-Risk Group.

Patel HD, Tosoian JJ, Carter HB, Epstein JI.

JAMA Oncol. 2018 Jan 1;4(1):89-92. doi: 10.1001/jamaoncol.2017.1879.

24.

Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance.

Tosoian JJ, Patel HD, Mamawala M, Landis P, Wolf S, Elliott DJ, Epstein JI, Carter HB, Ross AE, Sokoll LJ, Pavlovich CP.

Prostate Cancer Prostatic Dis. 2017 Sep;20(3):339-342. doi: 10.1038/pcan.2017.16. Epub 2017 Apr 18.

25.

Comparison of Biochemical Recurrence-Free Survival after Radical Prostatectomy Triggered by Grade Reclassification during Active Surveillance and in Men Newly Diagnosed with Similar Grade Disease.

Diniz CP, Landis P, Carter HB, Epstein JI, Mamawala M.

J Urol. 2017 Sep;198(3):608-613. doi: 10.1016/j.juro.2017.03.122. Epub 2017 Mar 24.

PMID:
28347771
27.

Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.

Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, Ghabili K, Agostino J, Macura KJ, Carter HB, Schaeffer EM, Partin AW, Sokoll LJ, Ross AE.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):228-233. doi: 10.1038/pcan.2016.72. Epub 2017 Jan 24.

28.

Prostate Health Index density improves detection of clinically significant prostate cancer.

Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, Ghabili K, Mamawala M, Agostino J, Carter HB, Partin AW, Sokoll LJ, Ross AE.

BJU Int. 2017 Dec;120(6):793-798. doi: 10.1111/bju.13762. Epub 2017 Feb 6.

29.

Active Surveillance of Localized Prostate Cancer: Acknowledging Uncertainty.

Tosoian JJ, Carter HB.

J Clin Oncol. 2016 Dec 20;34(36):4452. Epub 2016 Oct 31. No abstract available.

PMID:
27998229
30.

Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.

Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, Ewing CM, Zhang L, Novakovic K, Petkewicz J, Gulukota K, Helseth DL Jr, Quinn M, Humphries E, Wiley KE, Isaacs SD, Wu Y, Liu X, Zhang N, Wang CH, Khandekar J, Hulick PJ, Shevrin DH, Cooney KA, Shen Z, Partin AW, Carter HB, Carducci MA, Eisenberger MA, Denmeade SR, McGuire M, Walsh PC, Helfand BT, Brendler CB, Ding Q, Xu J, Isaacs WB.

Eur Urol. 2017 May;71(5):740-747. doi: 10.1016/j.eururo.2016.11.033. Epub 2016 Dec 15.

31.

Editorial Comment.

Tosoian JJ, Alam R, Carter HB.

J Urol. 2016 Dec;196(6):1658. doi: 10.1016/j.juro.2016.06.105. Epub 2016 Sep 15. No abstract available.

PMID:
27639611
32.

Qualitative study on decision-making by prostate cancer physicians during active surveillance.

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

BJU Int. 2017 Jul;120(1):32-39. doi: 10.1111/bju.13651. Epub 2016 Oct 2.

33.

A Bayesian hierarchical model for prediction of latent health states from multiple data sources with application to active surveillance of prostate cancer.

Coley RY, Fisher AJ, Mamawala M, Carter HB, Pienta KJ, Zeger SL.

Biometrics. 2017 Jun;73(2):625-634. doi: 10.1111/biom.12577. Epub 2016 Aug 22.

PMID:
27548645
34.

Prediction of the Pathologic Gleason Score to Inform a Personalized Management Program for Prostate Cancer.

Coley RY, Zeger SL, Mamawala M, Pienta KJ, Carter HB.

Eur Urol. 2017 Jul;72(1):135-141. doi: 10.1016/j.eururo.2016.08.005. Epub 2016 Aug 11.

PMID:
27523594
35.

Risk prediction tool for grade re-classification in men with favourable-risk prostate cancer on active surveillance.

Mamawala MM, Rao K, Landis P, Epstein JI, Trock BJ, Tosoian JJ, Pienta KJ, Carter HB.

BJU Int. 2017 Jul;120(1):25-31. doi: 10.1111/bju.13608. Epub 2016 Aug 29.

36.

Optimizing Active Surveillance.

Carter HB.

Eur Urol. 2016 Dec;70(6):909-911. doi: 10.1016/j.eururo.2016.07.017. Epub 2016 Jul 22.

PMID:
27460354
37.

The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance.

Ma TM, Tosoian JJ, Schaeffer EM, Landis P, Wolf S, Macura KJ, Epstein JI, Mamawala M, Carter HB.

Eur Urol. 2017 Feb;71(2):174-180. doi: 10.1016/j.eururo.2016.05.021. Epub 2016 May 25.

PMID:
27236496
38.

PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.

Trock BJ, Fedor H, Gurel B, Jenkins RB, Knudsen BS, Fine SW, Said JW, Carter HB, Lotan TL, De Marzo AM.

Mod Pathol. 2016 Jul;29(7):764-71. doi: 10.1038/modpathol.2016.63. Epub 2016 Apr 15.

39.

Improving Prostate Cancer Screening and Diagnosis: Health Policy and Biomarkers Beyond PSA.

Patel HD, Chalfin HJ, Carter HB.

JAMA Oncol. 2016 Jul 1;2(7):867-8. doi: 10.1001/jamaoncol.2016.0170. No abstract available.

PMID:
27031887
40.

Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Tosoian JJ, Carter HB, Lepor A, Loeb S.

Nat Rev Urol. 2016 Apr;13(4):205-15. doi: 10.1038/nrurol.2016.45. Epub 2016 Mar 8. Review.

41.

Reply to M.C. Scholz et al.

Carter HB.

J Clin Oncol. 2016 Apr 10;34(11):1284. doi: 10.1200/JCO.2015.65.9755. Epub 2016 Feb 16. No abstract available.

PMID:
26884568
42.

Stromal Tumor of Uncertain Malignant Potential (STUMP) With PSA >500 ng/ml: A Case Report.

Johnson MH, Carter HB.

Urol Case Rep. 2015 Jul 15;3(5):175-7. doi: 10.1016/j.eucr.2015.06.012. eCollection 2015 Sep.

43.

Reply.

Reese AC, Carter HB.

Urology. 2015 Nov;86(5):997. doi: 10.1016/j.urology.2015.07.044. No abstract available.

PMID:
26590041
44.

Magnetic Resonance-Guided Prostate Biopsy.

Dianat SS, Carter HB, Macura KJ.

Magn Reson Imaging Clin N Am. 2015 Nov;23(4):621-31. doi: 10.1016/j.mric.2015.05.005. Epub 2015 Jul 9. Review.

PMID:
26499279
45.

Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.

Tosoian JJ, Sundi D, Trock BJ, Landis P, Epstein JI, Schaeffer EM, Carter HB, Mamawala M.

Eur Urol. 2016 Apr;69(4):576-581. doi: 10.1016/j.eururo.2015.09.032. Epub 2015 Oct 9.

PMID:
26456680
46.

Association of quantitative magnetic resonance imaging parameters with histological findings from MRI/ultrasound fusion prostate biopsy.

Dianat SS, Carter HB, Schaeffer EM, Hamper UM, Epstein JI, Macura KJ.

Can J Urol. 2015 Oct;22(5):7965-72.

PMID:
26432966
47.

A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype.

Zhu G, Liu Z, Epstein JI, Davis C, Christudass CS, Carter HB, Landis P, Zhang H, Chung JY, Hewitt SM, Miller MC, Veltri RW.

Cancer Epidemiol Biomarkers Prev. 2015 Dec;24(12):1864-72. doi: 10.1158/1055-9965.EPI-15-0496. Epub 2015 Sep 24.

48.

Predictors of Adverse Pathology in Men Undergoing Radical Prostatectomy Following Initial Active Surveillance.

Reese AC, Feng Z, Landis P, Trock BJ, Epstein JI, Carter HB.

Urology. 2015 Nov;86(5):991-5. doi: 10.1016/j.urology.2015.07.039. Epub 2015 Aug 31.

PMID:
26335496
49.

Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.

Tosoian JJ, Mamawala M, Epstein JI, Landis P, Wolf S, Trock BJ, Carter HB.

J Clin Oncol. 2015 Oct 20;33(30):3379-85. doi: 10.1200/JCO.2015.62.5764. Epub 2015 Aug 31.

50.

¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.

Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, Guner G, Munari E, Partin AW, Pavlovich CP, Han M, Carter HB, Bivalacqua TJ, Blackford A, Holt D, Dannals RF, Netto GJ, Lodge MA, Mease RC, Pomper MG, Cho SY.

J Nucl Med. 2015 Jul;56(7):1003-1010. doi: 10.2967/jnumed.115.154336. Epub 2015 Jun 11.

Supplemental Content

Loading ...
Support Center